| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
51,330,000 |
| Market
Cap: |
11.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2235 - $0.2235 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. Co.'s product candidate, FMX114, which is being evaluated for the potential treatment of mild-to-moderate atopic dermatitis. Co. is also in the preclinical stages of developing products containing Bromodomain and Extra-Terminal Domain (BET) inhibitor compounds. Co.'s initial BET inhibitor candidate in development is VYN201, an administered pan-BET inhibitor, which it is exploring in various immuno-inflammatory diseases, including skin diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
13,000 |
43,000 |
| Total Buy Value |
$0 |
$0 |
$50,778 |
$125,458 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
1 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Basta Steven L |
Director |
– • – |
2020-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
14,499 |
536,537 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2020-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
118,683 |
175,186 |
|
- |
|
| Hirsch Stanley |
Director |
– • – |
2020-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
135,147 |
201,410 |
|
- |
|
| Hirsch Stanley |
Director |
– • – |
2020-04-03 |
4 |
A |
$0.00 |
$0 |
I/I |
220,496 |
328,609 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2020-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
391,489 |
578,985 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2020-03-31 |
4 |
D |
$2.68 |
$4,524 |
D/D |
(1,688) |
56,503 |
|
- |
|
| Wiley Matthew T. |
Chief Commercial Officer |
• – – |
2020-03-31 |
4 |
D |
$2.68 |
$1,407 |
D/D |
(525) |
67,051 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2020-03-31 |
4 |
D |
$2.68 |
$5,199 |
D/D |
(1,940) |
59,452 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2020-03-31 |
4 |
D |
$2.68 |
$11,942 |
D/D |
(4,456) |
187,496 |
|
- |
|
| Saik Andrew |
Chief Financial Officer |
• – – |
2020-03-23 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
| Edelman Joseph |
Director |
– • • |
2020-03-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
20,173,708 |
|
-45% |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2020-03-09 |
4 |
A |
$0.00 |
$0 |
D/D |
58,191 |
58,191 |
|
- |
|
| Hirsch Stanley |
Director |
– • – |
2020-03-09 |
4 |
A |
$0.00 |
$0 |
D/D |
66,263 |
66,263 |
|
- |
|
| Hirsch Stanley |
Director |
– • – |
2020-03-09 |
4 |
A |
$0.00 |
$0 |
I/I |
108,113 |
108,113 |
|
- |
|
| Hadar Ilan |
CFO and Country Manager |
• – – |
2020-03-09 |
4 |
A |
$0.00 |
$0 |
D/D |
77,351 |
77,351 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2020-03-09 |
4 |
A |
$0.00 |
$0 |
D/D |
191,952 |
191,952 |
|
- |
|
| Basta Steven L |
Director |
– • – |
2020-03-09 |
4 |
A |
$0.00 |
$0 |
D/D |
7,108 |
522,038 |
|
- |
|
| Bruno Anthony D |
Director |
– • – |
2020-03-09 |
4 |
A |
$0.00 |
$0 |
D/D |
44,433 |
44,433 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2020-03-09 |
4 |
A |
$0.00 |
$0 |
D/D |
61,392 |
61,392 |
|
- |
|
| Wiley Matthew T. |
Chief Commercial Officer |
• – – |
2020-03-09 |
4 |
A |
$0.00 |
$0 |
D/D |
67,576 |
67,576 |
|
- |
|
| Ball Kristine M |
See Remarks |
• – – |
2019-12-11 |
4 |
D |
$4.52 |
$125,502 |
D/D |
(27,766) |
52,534 |
|
- |
|
| Ball Kristine M |
See Remarks |
• – – |
2019-12-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
80,300 |
80,300 |
|
- |
|
| Kwon Paul |
Chief Scientific Officer |
• – – |
2019-12-11 |
4 |
D |
$4.52 |
$125,502 |
D/D |
(27,766) |
52,534 |
|
- |
|
| Kwon Paul |
Chief Scientific Officer |
• – – |
2019-12-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
80,300 |
80,300 |
|
- |
|
| Krasnow Ronald A. |
See Remarks |
• – – |
2019-12-11 |
4 |
D |
$4.52 |
$37,385 |
D/D |
(8,271) |
15,819 |
|
- |
|
165 Records found
|
|
Page 6 of 7 |
|
|
